このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Pharvaris 将来の成長

Future 基準チェック /06

Pharvaris利益と収益がそれぞれ年間32.9%と69.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-77.9% 35.8%なると予測されています。

主要情報

8.9%

収益成長率

14.6%

EPS成長率

Pharmaceuticals 収益成長	23.7%
収益成長率	74.1%
将来の株主資本利益率	-93.4%
アナリストカバレッジ	Good
最終更新日	19 Sep 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

NasdaqGS:PHVS - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	8	-165	-190	-168	6
12/31/2025	N/A	-153	-165	-142	5
12/31/2024	N/A	-127	-133	-116	5
6/30/2024	N/A	-114	-99	-99	N/A
3/31/2024	N/A	-106	-92	-92	N/A
12/31/2023	N/A	-101	-93	-93	N/A
9/30/2023	N/A	-107	-90	-90	N/A
6/30/2023	N/A	-92	-81	-81	N/A
3/31/2023	N/A	-83	-75	-74	N/A
12/31/2022	N/A	-76	-67	-67	N/A
9/30/2022	N/A	-49	-59	-59	N/A
6/30/2022	N/A	-50	-54	-54	N/A
3/31/2022	N/A	-53	-52	-52	N/A
12/31/2021	N/A	-43	-45	-45	N/A
9/30/2021	N/A	-41	-41	-41	N/A
6/30/2021	N/A	-38	-38	-38	N/A
3/31/2021	N/A	-29	-29	-29	N/A
12/31/2020	N/A	-26	-22	-21	N/A
9/30/2020	N/A	-19	-16	-16	N/A
12/31/2019	N/A	-8	-7	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PHVS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PHVS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PHVS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PHVS来年は収益がないと予測されています。

高い収益成長: PHVS来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PHVS 3 年以内に赤字になると予測されています。

Pharvaris 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Pharvaris N.V. Announces Resignation of Morgan Conn as Chief Business Officer, Effective October 4, 2024

Co-Founder notifies of intention to sell stock

Pharvaris Expands Development Program for Deucrictibant

Co-Founder notifies of intention to sell stock

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris N.V. Appoints David Nassif as Permanent Chief Legal Officer

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris N.V., Annual General Meeting, Jun 28, 2024

Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses

Pharvaris N.V. Announces Chief Legal Officer Changes, Effective June 1, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Share price stability

Chief Early Development Officer notifies of intention to sell stock

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Independent Vice Chairman notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Pharvaris: Digging Deep For Sufficient Market Size

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023

New major risk - Shareholder dilution

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Co-Founder notifies of intention to sell stock

Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer

New major risk - Revenue and earnings growth

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Announces Board Changes

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

Pharvaris Announces Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Pharvaris N.V., Annual General Meeting, Jun 23, 2023

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

Less than half of directors are independent

Pharvaris Presents Data Supporting HAE Drug Development Strategy At the 2022 HAEi Global Leadership Workshop

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris GAAP EPS of -€0.38

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V., Annual General Meeting, Jun 29, 2022

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris N.V. Appoints Joan Schmidt as Chief Legal Officer

Less than half of directors are independent

High number of new and inexperienced directors

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris reports Q1 results

Independent Non-Executive Director has left the company

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE

Pharvaris B.V. has completed an IPO in the amount of $165.41 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘